Background
==========

Lung cancer is the leading cause of cancer-related mortality \[[@b1-medscimonit-25-4264]\]. According to the histology, lung cancer is divided into 2 main subtypes: small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), accounting for 15% and 85% of all cases, respectively \[[@b2-medscimonit-25-4264]\]. Among NSCLC, lung adenocarcinoma (LUAD) is one of the most common types of lung cancer, and is characterized by distinct cellular and molecular features, including gland and/or duct formation and/or production of significant amounts of mucus. Surgery is the standard treatment for early NSCLC \[[@b3-medscimonit-25-4264]\]. Besides chemotherapy and radiotherapy, the presence of targeted drugs significantly increases the overall survival of patients with advanced NSCLC, especially for LUAD \[[@b4-medscimonit-25-4264]\], but there is still a risk of recurrence in early postoperative lung cancer patients \[[@b5-medscimonit-25-4264]\]. Meanwhile, chemotherapy and targeted therapies are faced with extensive drug resistance \[[@b6-medscimonit-25-4264],[@b7-medscimonit-25-4264]\]. Thus, to understand the causes of drug resistance, establish methods of overcoming drug resistance and exploring new therapeutic targets have become important topics in the field of lung cancer.

Family with sequence similarity 83, member A (FAM83A), also known as BJ-TSA-9 \[[@b8-medscimonit-25-4264]\], is located on chromosome 8, locus q24.13, and spans 27 566 base pairs. There is a promoter approximately 4000 base pairs upstream as predicted by the ElDorado tool by Genomatix. Deletions in this part of the chromosome, including the FAM83A gene, often result in Langer-Giedion syndrome \[[@b9-medscimonit-25-4264]\]. Recently, some studies have found that dysregulated FAM83A is a potential biomarker in lung, prostate, and bladder cancers \[[@b8-medscimonit-25-4264],[@b10-medscimonit-25-4264],[@b11-medscimonit-25-4264]\]. However, the exact expression levels of FAM83A in LUAD and its clinical prognostic value have been unknown.

Therefore, in the present study, bioinformatics methods were performed initially to predict the differential expression levels of FAM83A mRNA in LUAD and normal lung tissues through mining cancer-related databases (TCGA and Oncomine). Then, immunohistochemical staining was carried out to examine the FAM83A protein expression levels in 83 cases of LUAD combined with paired normal tissues. Moreover, the chi-square test was used to investigate the relationship between clinicopathologic parameters and differential expression levels of FAM83A protein in LUAD. Additionally, Kaplan-Meier univariate and Cox multivariate survival analyses were used to identify the prognostic value of FAM83A expression in LUAD patients.

Material and Methods
====================

Bioinformatics mining
---------------------

We downloaded 483 cases of LUAD and 347 cases of normal lung tissues containing FAM83A mRNA expression information from the TCGA database (*<https://cancergenome.nih.gov/>*). Then, RStudio software was used to analyze the differential expression levels of FAM83A mRNA between groups and draw the overall survival (OS) and disease-free survival (DFS) curves. The Oncomine database (*<https://www.oncomine.org>*) \[[@b12-medscimonit-25-4264]\] was also screened to explore the differential expression levels of FAM83A between LUAD and normal groups. A total of 4 GEO-sourced datasets were included. Additionally, Kaplan-Meier Plotter (*<http://kmplot.com/analysis/index.php?p=service&cancer=lung>*) \[[@b13-medscimonit-25-4264]\] was used to draw the OS and DFS curves based on the GEO data.

Collected LUAD tissues and patients' clinicopathological data
-------------------------------------------------------------

We retrospectively collected 83 cases of LUAD and matched adjacent normal lung tissues for immunohistochemical staining. All the patients had received radical surgery in the Department of Cardiovascular Surgery in our hospital from January 2006 to December 2012. The last follow-up time was June 2017. The last pathologic diagnosis of all patients was LUAD after surgery. As listed in [Table 1](#t1-medscimonit-25-4264){ref-type="table"}, besides FAM83A expression levels, the corresponding clinical information of patients, including sex, age, T stage, and TNM stage, was concluded in detail. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University and informed consent was obtained from each patient.

Immunohistochemistry and judging of results
-------------------------------------------

According to the manufacturer's protocol, immunohistochemistry analysis was performed to investigate the differential expression levels of FAM83A in 83 cases of LUAD and matched normal lung tissues. FAM83A monoclonal antibody (ab128245) was purchased from Abcam Corporation and its working concentration was 1: 200. The results of immunohistochemical staining were independently judged and interpreted by 2 pathologists who were double-blinded. Based on methods used in previous other studies \[[@b14-medscimonit-25-4264]--[@b16-medscimonit-25-4264]\], the immunoreaction score (IRS) was calculated from each slice, with the IRS equal to staining intensity (SI)×number of stained cells (PP). IRS scores ranged from 0 to 12. When the IRS was larger than 4, FAM83A was defined as high expression, and with IRS ≤4, FAM83A was defined as low expression.

Statistical analysis
--------------------

SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA) was used to statistically analyze the experimental data. Mean and standard deviation were used to express the quantitative data. TCGA and Oncomine data were analyzed using the independent-samples *t* test to compare the differential expression levels of FAM83A mRNA between LUAD and normal lung tissue groups. The chi-square test was used to analyze the correlation between FAM83A differential levels and clinicopathological factors of LUAD patients. Kaplan-Meier univariate and Cox multivariate survival analyses were used to verify the prognostic value of FAM83A differential levels in LUAD patients. If the *P* value was less than 0.05, the difference was considered statistically significant.

Results
=======

FAM83A was overexpressed in LUAD compared to normal lung tissues
----------------------------------------------------------------

Through mining the TCGA data, we found that FAM83A mRNA expression levels were significantly higher in LUAD than those in normal lung tissues (*P*\<0.05, [Figure 1A](#f1-medscimonit-25-4264){ref-type="fig"}). By searching the Oncomine database, a total of 4 GEO-sourced datasets were found. The meta-analysis revealed that FAM83A mRNA levels were dramatically higher in LUAD than in normal lung tissues (*P*=3.38E-13, [Figure 1B](#f1-medscimonit-25-4264){ref-type="fig"}). Moreover, as shown in [Figure 2](#f2-medscimonit-25-4264){ref-type="fig"}, results from each dataset were consistent with findings of the above meta-analysis.

Then, to confirm the above predictive results, immunohistochemistry was carried out. As shown in [Figure 3A](#f3-medscimonit-25-4264){ref-type="fig"}, FAM83A was positively stained in cytoplasm and cytomembrane of LUAD cells and the high positive rate of FAM83A staining in LUAD was 73.49% (61/83), while that of matched normal lung tissues was only 22.89% (19/83) ([Figure 3B](#f3-medscimonit-25-4264){ref-type="fig"}). Levels of FAM83A protein were remarkably higher in LUAD than those in matched normal lung tissues (χ^2^=42.562, *P*=0.000, [Table 2](#t2-medscimonit-25-4264){ref-type="table"}).

Association between FAM83A differential levels and clinicopathological factors of LUAD patients
-----------------------------------------------------------------------------------------------

Based on the immunohistochemical staining results, chi-square testing was done for FAM83A protein differential levels (low *vs.* high) and different subgroups of each clinicopathological factors. As shown in [Table 1](#t1-medscimonit-25-4264){ref-type="table"}, there was no significant difference in FAM83A expression levels between the 2 subgroups of clinicopathological factor in LUAD patients (All *P*\>0.05).

Potential prognostic value of FAM83A gene in LUAD patients
----------------------------------------------------------

As shown in [Figure 4](#f4-medscimonit-25-4264){ref-type="fig"}, through mining the TCGA database and use of Kaplan-Meier Plotter, we found that LUAD patients with high levels of FAM83A mRNA had dramatically decreased OS and DFS compared to those with low levels of FAM83A mRNA (All *P* values \<0.05, the cut-off value of FAM83A mRNA expression was set as 50%). Then, immunohistochemistry was performed to verify the predictive results. Kaplan-Meier survival analysis showed that LUAD patients with high levels of FAM83A protein had remarkably lower OS than those with low levels of FAM83A protein (*P*=0.002, [Figure 5](#f5-medscimonit-25-4264){ref-type="fig"}). Log-rank univariate survival analysis demonstrated that together with FAM83A differential levels, lymph node metastasis, T stage, TNM stage, and EGFR status were all the statistically significant parameters affecting the OS of LUAD patients ([Table 3](#t3-medscimonit-25-4264){ref-type="table"}). Additionally, the above 5 factors were used in the subsequent Cox multivariate survival analysis, showing that FAM83A differential expression level (low *vs.* high) was the only independent factor predicting the prognosis of LUAD patients (*P*=0.001, [Table 4](#t4-medscimonit-25-4264){ref-type="table"}).

Discussion
==========

Recently, accumulating studies have found that FAM83A was overexpressed in some malignancies \[[@b17-medscimonit-25-4264],[@b18-medscimonit-25-4264]\], including lung \[[@b8-medscimonit-25-4264],[@b10-medscimonit-25-4264],[@b19-medscimonit-25-4264]\], breast \[[@b20-medscimonit-25-4264]--[@b23-medscimonit-25-4264]\], pancreatic \[[@b24-medscimonit-25-4264]\], and ovarian cancer \[[@b25-medscimonit-25-4264]\]. Researchers observed that the FAM83A gene might be a good candidate for early detection of these cancers, especially lung cancer \[[@b8-medscimonit-25-4264],[@b10-medscimonit-25-4264]\]. Lee et al. \[[@b20-medscimonit-25-4264]\] revealed that FAM83A conferred EGFR-TKI drug resistance in breast cancer cells and in mice, and the underlying mechanisms were that FAM83A could interact with and cause phosphorylation of c-RAF and PI3K p85, upstream of MAPK and downstream of EGFR. Boyer et al. \[[@b21-medscimonit-25-4264]\] performed the quantitative proteomics with siRNA screening, showing that FAM83A and MAPK1 were both involved in the trastuzumab resistance in HER2-positive breast cancers, and similar findings were observed by Bartel et al. \[[@b22-medscimonit-25-4264]\]. Moreover, FAM83A overexpression was closely linked to the development, high disease stage, presence of distant metastasis, and poor prognosis in breast cancer \[[@b23-medscimonit-25-4264]\]. Recently, Ning et al. \[[@b26-medscimonit-25-4264]\] used the TCGA dataset to perform an integrated genomic analysis of lung squamous cell carcinoma, and found that 6 ceRNAs (PLAU, miR-31-5p, miR-455-3p, FAM83A-AS1, MIR31HG, and MIR99AHG) were significantly correlated patient survival. However, the expression levels of FAM83A in LUAD and its prognostic value have not been investigated in detail.

Therefore, in the present study, the bioinformatics mining method was used to examine the differential expression of FAM83A mRNA between LUAD and normal lung groups based on TCGA and GEO (from Oncomine database) data. Results from TCGA and Oncomine databases revealed that FAM83A mRNA expression levels were significantly higher in the LUAD group than in the normal lung group. Then, to confirm the predictive results, immunohistochemistry was used to investigate the expression levels of FAM83A protein in 83 cases of LUAD and matched normal lung tissues. Identical with the above predictive findings, the high positive rate of FAM83A protein in LUAD was 73.49%, but was only 22.89% in the normal group. Compared to the normal group, the expression levels of FAM83A protein were dramatically higher in the LUAD group. All these results suggest that FAM83A is an oncogene involved in promoting the occurrence and development of LUAD.

Subsequently, the relationship between FAM83A and clinicopathological factors of LUAD patients and its potential clinical prognostic value were investigated. Through mining the TCGA database and use of Kaplan-Meier Plotter, we observed that LUAD patients with high FAM83A mRNA levels had dramatically lower OS and DFS time than those with low FAM83A mRNA levels. Based on the immunohistochemical data, Kaplan-Meier univariate survival analysis showed that LUAD patients with high levels of FAM83A protein had remarkably decreased OS times than those with low levels of FAM83A protein. Moreover, Cox multivariate survival analysis demonstrated that FAM83A differential expression levels (low *vs.* high) were the only independent factors predicting the prognosis of LUAD patients. In summary, these findings suggest that FAM83A overexpression could serve as an independent factor to predict the poor prognosis of LUAD patients, and FAM83A might be an important target gene involved in the growth and metastasis of LUAD.

The present study has certain deficiencies. First, the number of retrospectively collected samples was relatively small, and this might have influenced the statistical analysis to some extent. Second, some cell functional experiments, including cell proliferation, migration, and invasion, were not performed. Third, the underlying mechanisms of FAM83A overexpression in LUAD were not explored in this study. These limitations will be addressed in our future studies.

Conclusions
===========

Our study demonstrated that FAM83A was overexpressed in LUAD, and FAM83A overexpression could serve as an independent factor to predict the poor prognosis of LUAD patients. FAM83A may become a new potential therapeutic target for the treatment of LUAD.
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![Overexpression of FAM83A mRNA in LUAD predicted by TCGA and Oncomine databases. (**A**) FAM83A mRNA levels in LUAD *vs.* normal lung group; (**B**) Meta-analysis of the 4 datasets on FAM83A mRNA levels in LUAD *vs.* normal lung tissue by Oncomine database.](medscimonit-25-4264-g001){#f1-medscimonit-25-4264}

![Four datasets on FAM83A mRNA levels in LUAD *vs.* normal lung tissue by Oncomine database. The GSE number of each dataset was listed as follows: (**A**) *Okayama Lung* (GEO: GSE31210); (**B**) *Hou Lung* (GEO: GSE19188); (**C**) *Selamat Lung* (GEO: GSE32863); (**D**) *Garber Lung* (GEO: GSE3398).](medscimonit-25-4264-g002){#f2-medscimonit-25-4264}

![FAM83A protein levels in 83 cases of LUAD and matched adjacent normal lung tissues by immunohistochemical staining. (**A**) High expression of FAM83A in LUAD; (**B**) Low expression of FAM83A in matched normal lung tissue. Bar=50 um.](medscimonit-25-4264-g003){#f3-medscimonit-25-4264}

![Overall survival (OS) and disease-free survival (DFS) curves of LUAD patients based on the differential expression levels FAM83A mRNA (low *vs.* high). (**A**) OS curve based on TCGA data; (**B**) DFS curve based on TCGA data; (**C**) OS curve based on GEO data (analyzed in Kaplan-Meier Plotter website); (**D**) DFS curve based on GEO data (analyzed in Kaplan-Meier Plotter website).](medscimonit-25-4264-g004){#f4-medscimonit-25-4264}

![Overall survival (OS) curve of LUAD patients based on the immunohistochemical data under differential expression levels FAM83A protein (low *vs.* high).](medscimonit-25-4264-g005){#f5-medscimonit-25-4264}

###### 

Correlation between FAM83A and clinicopathological parameters of LUAD patients.

  Clinicopathological parameters   Cases (n)   FAM83A expression levels   χ^2^   *P* value   
  -------------------------------- ----------- -------------------------- ------ ----------- -------
  Gender                                                                                     
   Male                            42          11                         31     0.004       0.947
   Female                          41          11                         30                 
  Age (years)                                                                                
   ≤60                             39          9                          30     0.444       0.505
   \>60                            44          13                         31                 
  Histological differentiation                                                               
   Well/moderate                   58          16                         42     0.115       0.734
   Poor                            25          6                          19                 
  Tumor size (cm)                                                                            
   ≤3                              32          11                         21     1.655       0.198
   \>3                             51          11                         40                 
  Tumor location                                                                             
   Left lung                       34          10                         24     0.250       0.617
   Right lung                      49          12                         37                 
  Lymph node metastasis                                                                      
   No                              36          11                         25     0.535       0.464
   Yes                             47          11                         36                 
  T stage                                                                                    
   T1                              17          6                          11     0.848       0.357
   T2--T4                          66          16                         50                 
  TNM stage                                                                                  
   I                               27          7                          20     0.007       0.934
   II+III+IV                       56          15                         41                 
  EGFR status                                                                                
   Negative                        69          16                         53     2.311       0.128
   Positive                        14          6                          8                  

###### 

Overexpression of FAM83A in 83 cases of LUAD tissues.

  Tissues                  FAM83A expression levels (Cases, %)   χ^2^         *P*      
  ------------------------ ------------------------------------- ------------ -------- -------
  LUAD                     22 (26.51)                            61 (73.49)   42.562   0.000
  Matched normal tissues   64 (77.11)                            19 (22.89)            

###### 

Kaplan-Meier univariate survival analysis of FAM83A and other clinicopathological parameters in LUAD patients.

  Clinicopathological parameters   Mean survival time (months)   95% CI           *P* value
  -------------------------------- ----------------------------- ---------------- -----------
  FAM83A levels                                                                   
   Low                             79.286                        61.241--97.331   0.002
   High                            39.646                        32.438--46.854   
  Gender                                                                          
   Male                            49.569                        37.470--61.668   0.499
   Female                          56.247                        43.320--69.173   
  Age (years)                                                                     
   ≤60                             52.308                        39.446--65.170   0.971
   \>60                            53.146                        40.891--65.400   
  Histological differentiation                                                    
   Well/moderate                   53.040                        42.443--63.637   0.926
   Poor                            46.440                        33.717--59.163   
  Tumor size (cm)                                                                 
   ≤3                              62.759                        47.297--78.220   0.110
   \>3                             42.342                        34.249--50.436   
  Tumor location                                                                  
   Left lung                       48.324                        38.251--58.396   0.759
   Right lung                      52.478                        40.361--64.594   
  Lymph node metastasis                                                           
   No                              72.237                        57.350--87.125   0.000
   Yes                             35.560                        28.624--42.497   
  T stage                                                                         
   T1                              74.281                        52.032--96.530   0.030
   T2--T4                          42.730                        35.721--49.739   
  TNM stage                                                                       
   I                               75.748                        59.631--91.866   0.001
   II+III+IV                       37.119                        30.318--43.920   
  EGFR status                                                                     
   Negative                        56.976                        46.684--67.268   0.046
   Positive                        32.357                        21.979--42.735   

###### 

Cox multivariate analysis of FAM83A and other clinicopathological parameters in LUAD patients.

  Covariates                                 HR      95% CI for HR   P value
  ------------------------------------------ ------- --------------- ---------
  FAM83A expression level (low *vs.* high)   3.194   1.576--6.471    0.001
  Lymph node metastasis (no *vs.* yes)       1.294   0.585--2.864    0.524
  T stage (T1 *vs.* T2--T4)                  1.299   0.614--2.748    0.494
  TNM stage (I *vs.* II+III+IV)              1.857   0.781--4.420    0.162
  EGFR status (negative *vs.* positive)      1.904   0.942--3.846    0.073
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